Tubulin Identified as Key Player in Combating Alzheimer’s and Parkinson’s

Researchers have discovered a protein that could halt brain changes associated with Alzheimer’s and Parkinson’s diseases. The study, published in Nature Communications, highlights tubulin—a protein primarily known for constructing the cell’s internal framework.

Scientists at Baylor College of Medicine found tubulin’s capability to prevent harmful clumps from forming in brain cells. In Alzheimer’s disease, tau protein build-up is a concerning factor. Similarly, Parkinson’s disease involves alpha-synuclein aggregates. These proteins can misfold, creating toxic clusters that harm neurons, leading to memory loss, cognitive decline, and movement issues.

Traditional approaches focus on stopping or clearing these clumps. The new research suggests encouraging normal protein behavior might be more effective than blocking them altogether.

Dr. Ram Bishnoi, an associate professor of psychiatry and behavioral neurosciences, emphasized how the study provides a “concrete, testable mechanism” for this approach. Tubulin acts as a molecular switch, determining if tau and alpha-synuclein become toxic or remain useful, Bishnoi explained to Newsweek.

The team discovered tubulin’s interaction with tau and alpha-synuclein within cellular compartments known as condensates—droplets where both healthy and harmful protein versions coexist. When tubulin is present, it competes for binding sites, keeping these proteins in functional shapes, Bishnoi stated. In its absence, harmful clumping ensues.

Reducing tubulin levels in cell models showed increased harmful protein build-up and visible neuron loss, underscoring its protective role. The study indicates that the presence of tubulin, rather than eliminating condensates, is crucial. The condensate isn’t beneficial or harmful on its own; it’s about tubulin being in the environment, Bishnoi said.

This understanding could transform neurodegenerative disease treatments. Instead of eliminating harmful protein deposits entirely, scientists can potentially guide them towards beneficial behaviors. Established research acknowledges the normal roles of tau and alpha-synuclein in the brain. Entirely blocking these proteins risks disrupting healthy functions.

Bishnoi noted that this study supports a balanced approach. Instead of dissolving tau aggregates, the study asks how to keep tubulin levels high enough to prevent formation initially, he emphasized.

The findings correspond with clinical observations where microtubule networks diminish early in Alzheimer’s disease, suggesting this as a target for intervention. Nonetheless, laboratory and cell-model experiments necessitate confirmation through animal models and human studies.

Microtubule-targeting drugs are challenging to develop safely due to microtubules’ essential cellular roles throughout the body, Bishnoi noted. Animal studies are the logical next step. Despite challenges, the research provides clearer guidance for future exploration.

Bishnoi suggested considering tubulin as a potential lever in treatment strategies, rather than a proven solution, in strengthening the ‘redirect rather than demolish’ strategy, he concluded.